Generation of a strong anti-HER2 Th1 immune response in the tumor draining lymph node, spleen and peripheral blood are critical for the inhibitory effect of the combination treatment with HER2-DC1 i.t. and anti-HER2 antibodies on tumor growth, which was supported by detection of increased Th1 cytokines IFN-γ and TNF-α. Here, ERBB2 is linked to neoplasm.